Please ensure Javascript is enabled for purposes of website accessibility

Why Dyax Corp Rocketed 22% Higher in November

By Brian Feroldi – Dec 7, 2015 at 2:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A buyout offer from a rival firm has Dyax shareholders seeing green.

What: Investors in Dyax Corp (NASDAQ: DYAX), a drug developer with a focus on rare diseases, had a terrific November. The company's share price shot up by more than 22% during the period, according to data from S&P Capital IQ.

DYAX Chart

So what: The huge jump was catalyzed by news that Shire PLC (NASDAQ: SHPG) would be acquiring Dyax for $5.9 billion, or $37.30 per share, in an all-cash deal.

As part of the transaction, shareholders of Dyax will also receive a contingent value right that could entitle them to additional $4.00 per share in cash if the company's lead drug, DX-2930, manages to win FDA approval before Dec. 31, 2019.

Now what: The huge premium Shire paid to make this deal happen clearly indicates huge expectations for DX-2930. This compound is being researched as a treatment for hereditary angiodema, or HAE, a life-threatening rare genetic disease that causes swelling in the face, extremities, and GI tract. In early clinical studies, DX-2930 was able to reduce HAE attacks by 90% compared to placebo, a result that was impressive enough for the FDA to grant the drug with Fast Track, Breakthrough Therapy, and Orphan Drug designations.

If all goes well from here, then Shire anticipates that this drug could generate worldwide global sales around $2.0 billion. Since Shire already commands a dominant leadership position in the HAE market, there is plenty of reason to believe its estimate is correct.

Shire expects this transaction will be dilutive to its earnings for the next two years and will become accretive in 2018 and beyond.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.